Pegvisomant

DB00082

biotech approved

Deskripsi

Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) ~6 days
Volume Distribusi * 7 L
Klirens (Clearance) * 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

522 Data
Insulin human The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glargine.
Insulin pork The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.
Troglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Troglitazone.
Glimepiride The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glimepiride.
Sulfisoxazole The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfisoxazole.
Disopyramide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide.
Acarbose The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acarbose.
Metformin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.
Sulfadiazine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rosiglitazone.
Acetohexamide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acetohexamide.
Quinine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Quinine.
Miglitol The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Miglitol.
Chlorpropamide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Chlorpropamide.
Nateglinide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nateglinide.
Pentamidine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pentamidine.
Mifepristone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mifepristone.
Tolazamide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolazamide.
Repaglinide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide.
Phenformin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Phenformin.
Sulfamethoxazole The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfamethoxazole.
Glyburide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glyburide.
Glipizide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glipizide.
Gliclazide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliclazide.
Tolbutamide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolbutamide.
Pioglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pioglitazone.
Bromocriptine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bromocriptine.
Gliquidone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliquidone.
Mitiglinide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mitiglinide.
Sitagliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sitagliptin.
Sunitinib The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sunitinib.
Exenatide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Exenatide.
Mecasermin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mecasermin.
Pramlintide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pramlintide.
Glisoxepide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glisoxepide.
Insulin aspart The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glulisine.
Glymidine The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glymidine.
AICA ribonucleotide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AICA ribonucleotide.
Buformin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Buformin.
Vildagliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Vildagliptin.
Voglibose The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Voglibose.
NN344 The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NN344.
AMG-222 The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AMG-222.
Bisegliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bisegliptin.
Alogliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alogliptin.
Dapagliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.
Saxagliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Saxagliptin.
Liraglutide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Liraglutide.
Gosogliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gosogliptin.
Linagliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.
Canagliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.
Glibornuride The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glibornuride.
Benfluorex The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Benfluorex.
Empagliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.
Albiglutide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Albiglutide.
Dulaglutide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.
Lobeglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lobeglitazone.
Netoglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Netoglitazone.
Rivoglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rivoglitazone.
Ciglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ciglitazone.
Lixisenatide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lixisenatide.
Insulin beef The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin degludec.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ipragliflozin.
Dutogliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dutogliptin.
Allicin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Allicin.
Tofogliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tofogliflozin.
Ertugliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ertugliflozin.
2,4-thiazolidinedione The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Teneligliptin.
Omarigliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Omarigliptin.
Carmegliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carmegliptin.
Gemigliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gemigliptin.
Anagliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Anagliptin.
Evogliptin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Evogliptin.
Sotagliflozin The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sotagliflozin.
Balaglitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carbutamide.
Guar gum The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Guar gum.
Metahexamide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metahexamide.
Semaglutide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Semaglutide.
Taspoglutide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Taspoglutide.
Englitazone The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Englitazone.
Tirzepatide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gastric inhibitory polypeptide.
Octreotide The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.
Vapreotide The risk or severity of increased transaminases can be increased when Vapreotide is combined with Pegvisomant.
Pasireotide The risk or severity of increased transaminases can be increased when Pasireotide is combined with Pegvisomant.
Lanreotide The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant.
Somatostatin The risk or severity of increased transaminases can be increased when Somatostatin is combined with Pegvisomant.
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Pegvisomant.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Pegvisomant.
Morphine The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.

Target Protein

Growth hormone receptor GHR

Referensi & Sumber

Synthesis reference: Mandayam J. Narasimhan, John A. Anderson, "Process for the large scale production of human growth hormone by serial secondary suspension culture." U.S. Patent US4124448, issued January, 1963.

Contoh Produk & Brand

Produk: 23 • International brands: 0
Produk
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 10 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 15 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 20 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 25 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 30 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 10 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 15 mg/1mL • Subcutaneous • US • Approved
  • Somavert
    Injection, powder, lyophilized, for solution; Kit • 20 mg/1mL • Subcutaneous • US • Approved
Menampilkan 8 dari 23 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul